AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28967984
Drug: SYM‐1219 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYM‐1219 2 g
Trial: 27440710
Drug: Zoledronate (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoledronate (5 mg intravenously once per year)
Trial: 27440710
Drug: Alendronate (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (70 mg orally once per week)
Trial: 24458543
Drug: Cognitive Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behaviour Therapy for Insomnia (CBT-I)
Trial: 20524443
Drug: Nicomild‐2 Sugar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicomild‐2 Sugar Free Gum (2 mg pieces, 6.74%)
Trial: 20524443
Drug: Nicorette Sugar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorette Sugar Free (2 mg pieces)
Trial: 18514508
Drug: Exemestane 25mg
RxNorm normalized name: EXEMESTANE 25MG TAB
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exemestane 25mg daily and celecoxib 400mg twice daily (group A)
Trial: 18514508
Drug: Exemestane 25mg
RxNorm normalized name: EXEMESTANE 25MG TAB
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exemestane 25mg daily (group B)
Trial: 18514508
Drug: Letrozole 2.5mg
RxNorm normalized name: LETROZOLE 2.5MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5mg daily (group C)
Trial: 16769438
Drug: Interviewer‐Administered Questionnaire
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interviewer‐Administered Questionnaire (IAQ)
Trial: 28873075
Drug: Magnesium infusion
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium infusion
Trial: 1495197
Drug: Cefdinir 3
RxNorm normalized name: cefdinir 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefdinir 3 mg/kg administered 1 hour before meal (fasting state)
Trial: 23588865
Drug: 5 mg/ml
RxNorm normalized name: urea 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/ml (total 2 ml) esmolol
Trial: 15166570
Drug: Morphine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0.1 mg
Trial: 15166570
Drug: Morphine 0.3
RxNorm normalized name: ethylmorphine 0.32 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0.3 mg
Trial: 12002497
Drug: Intravenous regional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous regional blockade (IVRB) with 15 mg of guanethidine in 30 ml of 0.5% prilocaine
Trial: 12002497
Drug: Serial IVRB
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serial IVRB with 30 ml of normal saline (control)
Trial: 1965420
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of itraconazole given in one single day
Trial: 1965420
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg once daily for three days
Trial: 6802327
Drug: Slow-release aminophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release aminophylline (14 mg/kg twice daily)
Trial: 30947585
Drug: Blinatumomab by
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinatumomab by continuous infusion for 4 weeks in 6‐week cycles
Trial: 30947585
Drug: Standard salvage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard salvage chemotherapy
Trial: 9293649
Drug: Epidural butorphanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural butorphanol 0.5 mg
Trial: 9293649
Drug: Epidural butorphanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural butorphanol 0.5 mg plus clonidine 75 micrograms
Trial: 2825502
Drug: Fiber supplements
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fiber supplements (three different types)
Trial: 24621255
Drug: Exenatide BID
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide BID (5 µg for 4 weeks, then 10 µg ongoing)
Trial: 16398429
Drug: Shengmai injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shengmai injection (SI)
Trial: 3059899
Drug: Theophylline at
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline at mean concentrations of 5.13, 12.07, and 18.6 micrograms/ml
Trial: 26277887
Drug: pioglitazone 30
RxNorm normalized name: pioglitazone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pioglitazone 30 mg once daily
Trial: 19604642
Drug: Low-dose ketamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ketamine (22.2±2.0 mg/h/70 kg)
Trial: 15456342
Drug: Intravenous anidulafungin
RxNorm normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous anidulafungin 50 mg/day
Trial: 15456342
Drug: Oral fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral fluconazole 100 mg/day
Trial: 11552994
Drug: Post-heparin prophylaxis
RxNorm normalized name: Anthrax, post-exposure prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-heparin prophylaxis (4 months after delivery)
Trial: 9522143
Drug: Prilocaine 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prilocaine 2% (6 mL)
Trial: 9522143
Drug: Bupivacaine 0.5%
RxNorm normalized name: BUPivacaine 0.5% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.5% (3 mL)
Trial: 2483435
Drug: Ibopamine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibopamine (100 mg t.i.d.)
Trial: 4423243
Drug: Permissively worded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permissively worded amnesia suggestions with hypnotic motivation
Trial: 4423243
Drug: Authoritatively worded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Authoritatively worded amnesia suggestions with hypnotic motivation
Trial: 17219155
Drug: Intracervical dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intracervical dinoprostone gel (0.5 mg every 6 h for a maximum of 24 h)
Trial: 15650341
Drug: Estrogen replacement
RxNorm normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen replacement therapy (0.625 mg conjugated estrogen)
Trial: 6318353
Drug: Bi-Profenid 300
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bi-Profenid 300 mg
Trial: 6318353
Drug: Oxyphenbutazone 400
RxNorm normalized name: oxyphenbutazone
DrugBank: Oxyphenbutazone (DB03585)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxyphenbutazone 400 mg
Trial: 31868813
Drug: 16 weekly
RxNorm normalized name: Weekly Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 weekly sets per muscle group (G16)
Trial: 31868813
Drug: 24 weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 weekly sets per muscle group (G24)
Trial: 31868813
Drug: 32 weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 32 weekly sets per muscle group (G32)
Trial: 16871748
Drug: Cimetidine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (3 x 200 mg + 400 mg after 12 h)
Trial: 7624262
Drug: Famotidine 40
RxNorm normalized name: famotidine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 40 mg
Trial: 9917431
Drug: Sn-mesoporphyrin (SnMP)
RxNorm normalized name: Sn Mesoporphyrin
DrugBank: Stannsoporfin (DB04912)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sn-mesoporphyrin (SnMP) 6.0 micromol/kg birth weight, single dose, intramuscular
Trial: 8014496
Drug: Alternating combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating combination regimen of chronic ganciclovir-foscarnet therapy
Trial: 29384322
Drug: Daily isoflavone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily isoflavone supplementation (50 mg/day aglycone daidzein and genistein) with two green kiwifruit
Trial: 29384322
Drug: Daily isoflavone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily isoflavone supplementation (50 mg/day aglycone daidzein and genistein) alone
Trial: 21392600
Drug: Extended-release niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release niacin
Trial: 10718203
Drug: Metrifonate (125-225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metrifonate (125-225 mg loading dose for 2 weeks, followed by 50-90 mg maintenance dose for 4 weeks)
Trial: 29362276
Drug: Integrated medicines
RxNorm normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated medicines management (IMM) intervention including medication reconciliation, review, counselling, medication list, and post-discharge calls.
Trial: 25904041
Drug: BMS‐820836 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS‐820836 2 mg once daily for 14 days
Trial: 25904041
Drug: BMS‐820836 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS‐820836 4 mg once daily for 14 days
Trial: 21216314
Drug: Plans to
RxNorm normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Plans to increase vaccine purchases
Trial: 21216314
Drug: Stocking all
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stocking all adult vaccines
Trial: 8256309
Drug: Fermented milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented milk product (200 ml daily for six weeks)
Trial: 26686960
Drug: Anastrozole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole (1 mg/day)
Trial: 23200931
Drug: Buprenorphine Transdermal
RxNorm normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine Transdermal System (BTDS) 10 μg/hour
Trial: 23200931
Drug: Buprenorphine Transdermal
RxNorm normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine Transdermal System (BTDS) 20 μg/hour
Trial: 20965447
Drug: Adjunctive TMS
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjunctive TMS
Trial: 11181472
Drug: Tezosentan 100
RxNorm normalized name: TEZOSENTAN
DrugBank: Tezosentan (DB06558)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezosentan 100 mg/h
Trial: 458200
Drug: ADV‐4 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADV‐4 vaccine
Trial: 19345067
Drug: TNFalpha-antagonists
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: TNFalpha-antagonists
Trial: 16960171
Drug: Tomato extract
RxNorm normalized name: TOMATO EXTRACT CONTAINING LYCOPENE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato extract supplement drink (equivalent to 6 tomatoes)
Trial: 9248875
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg lorazepam as needed every 30 min for 4 h
Trial: 9248875
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg haloperidol as needed every 30 min for 4 h
Trial: 23743961
Drug: Iron (II)
RxNorm normalized name: iron(II) sulfate
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iron (II) sulfate (Fe2+), 5 mg Fe/kg/d
Trial: 9279680
Drug: Heparin-surface-modified (HSM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-surface-modified (HSM) PMMA intraocular lenses
Trial: 1948264
Drug: Proguanil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proguanil (200 mg/day) combined with sulfamethoxazole (1000 mg/day)
Trial: 1948264
Drug: Proguanil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proguanil (200 mg/day) combined with sulfamethoxazole (1500 mg/day)
Trial: 25778685
Drug: Alfacalcidol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol (0.5 μg/day)
Trial: 21161329
Drug: Preemptive warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive warfarin dose reduction (10-20%)
Trial: 19524987
Drug: Periprostatic nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periprostatic nerve block and intraprostatic local anesthesia with 5 ml 2% lidocaine
Trial: 19524987
Drug: Periprostatic nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periprostatic nerve block with 0.9% NaCl by intraprostatic injection
Trial: 8851903
Drug: Diuretic (D)
RxNorm normalized name: benazepril and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic (D)
Trial: 1792613
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (2-3 drugs)
Trial: 6349944
Drug: Broad-spectrum sunscreen
RxNorm normalized name: Titanium Dioxide 0.08 g in 1 g TOPICAL LOTION [ZO MEDICAL OCLIPSE-C Broad-Spectrum Sunscreen SPF 50]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broad-spectrum sunscreen agent
Trial: 30712444
Drug: One-session cognitive
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-session cognitive behavior treatment (CBT)
Trial: 27197690
Drug: Rituximab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (1 g intravenous on days 1 and 15, and after 26 weeks if needed)
Trial: 27197690
Drug: TNF inhibitor
RxNorm normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF inhibitor (adalimumab 40 mg subcutaneously every other week or etanercept 50 mg per week subcutaneously)
Trial: 17369792
Drug: Twice per
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice per week leg press exercise (n=11)
Trial: 23136
Drug: Propranolol 80
RxNorm normalized name: propranolol 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 80 mg orally
Trial: 23136
Drug: Metoprolol 100
RxNorm normalized name: metoprolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 100 mg orally
Trial: 23136
Drug: Practolol 200
RxNorm normalized name: (±)-practolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Practolol 200 mg orally
Trial: 23136
Drug: Pindolol 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol 0.05 mg/kg intravenously
Trial: 26358523
Drug: Trastuzumab with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab with chemotherapy
Trial: 23596888
Drug: Safflower peony
RxNorm normalized name: SAFFLOWER
DrugBank: Safflower (DB10905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safflower peony ointment single dosage scheme (2.16 g, 4 people; 4.32 g, 6 people; 6.48 g, 6 people; 8.62 g, 6 people; 11.46 g, 6 people; 15.24 g, 6 people) for 24 hours, once every day.
Trial: 23596888
Drug: Safflower peony
RxNorm normalized name: SAFFLOWER
DrugBank: Safflower (DB10905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safflower peony ointment multi-dosage scheme (8.62 g, 6 people; 11.46 g, 6 people) once every day for 7 days.
Trial: 21539525
Drug: Low Drug
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Drug Burden Index (DBI <1)
Trial: 21539525
Drug: High Drug
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Drug Burden Index (DBI ≥1)
Trial: 21539525
Drug: Low Drug
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Drug Burden Index (DBI <1) after adjustment
Trial: 12162857
Drug: Intravenous doxepin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous doxepin
Trial: 12162857
Drug: Oral doxepin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doxepin
Trial: 2349954
Drug: Oral L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral L-carnitine supplementation, 100 mg/kg/day for 2 months
Trial: 2349954
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no oral L-carnitine supplementation)
Trial: 159841
Drug: Ro 11‐1430
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 11‐1430 (0.1% vanishing cream)
Trial: 159841
Drug: Placebo (vanishing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vanishing cream alone)
Trial: 25594845
Drug: Barrier-improving cream
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barrier-improving cream (5% urea)
Trial: 25594845
Drug: Reference cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference cream
Trial: 24076337
Drug: 25% albumin
RxNorm normalized name: Flexbumin 25% Albumin (Human) Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% albumin (2 g/kg; maximum dose 750 mL)
Trial: 17038253
Drug: Glutamine +
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine + TPN (0.27 g.kg(‐1).d(‐1) for 7 days)
Trial: 153716
Drug: No EMG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No EMG treatment (control group)
Trial: 31416011
Drug: SSS07 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSS07 (5 mg, 15 mg, 30 mg, 50 mg, 75 mg, 100 mg)
Trial: 31416011
Drug: SSS07 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSS07 (5 mg to 100 mg)
Trial: 18574608
Drug: Polytherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polytherapy with two atypical antipsychotics
Trial: 18574608
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with atypical antipsychotics
Trial: 11966543
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (acid decreasing therapy with H2-receptor antagonist or PPI)
Trial: 11966543
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (one antibiotic plus acid-decreasing therapy)
Trial: 11966543
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (PPI plus amoxicillin and clarithromycin)
Trial: 9709461
Drug: Immediate AZT
RxNorm normalized name: AZT
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate AZT monotherapy
Trial: 9709461
Drug: Deferred AZT
RxNorm normalized name: AZT
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deferred AZT monotherapy
Trial: 8620950
Drug: Low-dose salbutamol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose salbutamol metered-dose inhaler (50 micrograms.puff-1)
Trial: 8620950
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose salbutamol metered-dose inhaler (100 micrograms.puff-1)
Trial: 25226426
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg/day)
Trial: 11130216
Drug: Citalopram 10
RxNorm normalized name: citalopram 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram 10 mg once/day for the first week, 20 mg once/day for the second week, and 40 mg once/day for the remaining 3 weeks
Trial: 9050976
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg moxonidine once a day (increased to 0.4 mg after 2 weeks)
Trial: 9050976
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg enalapril once a day (increased to 10 mg after 2 weeks)
Trial: 2243429
Drug: Colestipol-niacin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colestipol-niacin therapy
Trial: 29948418
Drug: TachoSil® patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TachoSil® patches
Trial: 22574800
Drug: Behaviour Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behaviour Therapy (BT)
Trial: 22086903
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy (n = 17), 100 minutes of conventional physical therapy daily.
Trial: 20592268
Drug: Fugl-Meyer score
RxNorm normalized name: meyer lemon extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fugl-Meyer score and treatment intensity
Trial: 16043733
Drug: Inhaled insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled insulin (INH) before meals
Trial: 8615554
Drug: Caffeine (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (two doses) with paracetamol
Trial: 4076324
Drug: Paracetamol alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol alone
Trial: 1679658
Drug: Terfenadine (H1-selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine (H1-selective histamine antagonist)
Trial: 1679658
Drug: Compound 48/80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound 48/80 (histamine depleting agent)
Trial: 7006883
Drug: Timolol 10
RxNorm normalized name: timolol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 10 to 30 mg twice daily